Claims
- 1. A method of treating parkinsonism which comprises administering to a host requiring such treatment an effective amount of a pharmaceutical composition comprising L-dopa, a peripheral decarboxylic inhibitor, a compound of the formula ##STR25## wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is --CO--R.sup.1 wherein R.sup.1 is a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 2. A method of treating parkinsonism, according to claim 1, wherein the compound is 3,4-dihydroxy-5-nitrobenzophenone.
- 3. A method of treating parkinsonism, according to claim 1, wherein the compound is 2'-fluoro-3,4-dihydroxy-5-nitrobenzophenone.
- 4. A method of treating parkinsonism according to claim 1, wherein the compound is 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone.
- 5. A method of treating Parkinson's Disease which comprises administering to a host requiring such treatment an effective amount of a pharmaceutical composition comprising L-dopa, a peripheral decarboxylase inhibitor, a compound of the formula ##STR26## wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is CO--R.sup.1 wherein R.sup.1 is a phenyl group optically mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 6. A method of treating parkinsonism according to claim 5, wherein the compound is 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone.
- 7. A method of treating Parkinson's disease, according to claim 6, wherein the compound is 3,4-dihydroxy-5-nitrobenzophenone.
- 8. A method of treating Parkinson's disease, according to claim 6, wherein the compound is 2'-fluoro-3,4-dihydroxy-5-nitrobenzophenone.
Priority Claims (2)
Number |
Date |
Country |
Kind |
980/86 |
Mar 1986 |
CHX |
|
62/87 |
Jan 1987 |
CHX |
|
Parent Case Info
This is a division of application Ser. No. 08/084,685 filed Apr. 16, 1993, now U.S. Pat. No. 5,389,653, which is a continuation of Ser. No. 07/686,210 filed Apr. 16, 1991, now U.S. Pat. No. 5,236,952, issued Aug. 17, 1993, which is a continuation of Ser. No. 07/395,110 filed Aug. 16, 1989, now abandoned, which is a continuation of Ser. No. 07/022,891 filed Mar. 6, 1987, now abandoned.
US Referenced Citations (7)
Foreign Referenced Citations (4)
Number |
Date |
Country |
79141 |
Oct 1982 |
EPX |
142283 |
May 1985 |
EPX |
967605 |
Aug 1964 |
GBX |
2038819 |
Dec 1978 |
GBX |
Non-Patent Literature Citations (13)
Entry |
Function and Regulation of Monoamine Enzymes, Basic and Clinical Aspects, MacMillian Publishers, 1981 657-664. |
Chemical Abstracts 92, 146461x (1980). |
Chemical Abstracts 98, 50111f (1983) and J. Antibiot. 35 (10) 1361-1366 (1982). |
J. Pharmacol. Exp. Ther. 174, 83-93 (1970). |
Biochem. Pharmacol. 28, 1221-1225 (1979). |
Arch. Pharmacol. 320, 34-37 (1982). |
J. Med. Chem 25, 258-263 (1982). |
J. Med. Chem. 25, 321-323 (1982). |
Registry Handbook 1965-1971 p. 10666R. |
CA 95: 135254t (1981). |
Miyamoto et al., Chem. Abstr. vol. 99 #121998 (1983). |
Chem. Abstracts vol. 115, No. 5, Abstract 49134d p. 790 Aug. 5, 1991 Bernauer, et al. |
Borgulya et al. Helv. Chim. Acta, vol. 72(5) pp. 952-968 (1989). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
48685 |
Apr 1993 |
|
Continuations (3)
|
Number |
Date |
Country |
Parent |
686210 |
Apr 1991 |
|
Parent |
395110 |
Aug 1989 |
|
Parent |
22891 |
Mar 1987 |
|